KalVista announces FDA acceptance of New Drug Application for sebetralstat for oral on-demand treatment of hereditary angioedema KalVista...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - PHARMABIZ.COM - A la Une - 23/Aug 00:00
US FDA clears ImmPACT Bio's IND application for CD19/CD20 bispecific CAR─T cell therapy in multiple sclerosis
ImmPACT Bio USA Inc. (ImmPACT Bio), a clinical─stage biopharmaceutical company, announced the United States Food and Drug Administration (FDA) has cleared an investigational new drug
Articles similaires
KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema
drugs.com - 03/Sep 20:09
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Sep. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S....
‘Significant milestone’ – EBR submits final PMA module to FDA
stockhead.com.au - 29/Aug 21:21
EBR Systems has submitted the final premarket approval (PMA) application module to the US Food and Drug Administration (FDA) for ...
Worldwide Clinical Trials - USA: Senior Clinical Research Associate* - CAR-T and Cell Therapy
pharmiweb.com - 00:00
Competitive: Worldwide Clinical Trials - USA: Who we are Worldwide Clinical Trials (Worldwide), a leading global contract research organization...
Worldwide Clinical Trials - USA: Senior Clinical Research Associate* - CAR-T and Cell Therapy
pharmiweb.com - 00:00
Competitive: Worldwide Clinical Trials - USA: Who we are Worldwide Clinical Trials (Worldwide), a leading global contract research organization...
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
financialpost.com - 01/Sep 12:03
Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural...
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
financialpost.com - 01/Sep 12:03
Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural...
Indies Pharma looking to double sales after securing FDA drug approval
jamaica-gleaner.com - 11/Sep 05:05
Drug company Indies Pharma Jamaica Limited is looking to double next year’s revenues, following approval of its abbreviated new drug application,...
Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
drugs.com - 03/Sep 01:09
LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...
Johnson & Johnson Seeks First Approval of Nipocalimab to Treat Broadest Population Living with Antibody Positive Generalized Myasthenia Gravis
drugs.com - 29/Aug 23:08
Spring House, Pa. (August 29, 2024) – Johnson & Johnson today announced the submission of a Biologics License Application (BLA) to the U.S. Food and...
Les derniers communiqués
-
Aucun élément